Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLL
Mikalai Katsin, Valeria M. Stepanova, Dmitri Dormeshkin, Alexandr A. Migas et autres
Abstract Background CD19-directed CAR-T cell therapy can induce durable remissions in chronic lymphocytic leukemia (CLL), but response rates are lower than in other B-cell malignancies, in part because CLL is characterized by T-cell dysfunction, defective immune synapse formation, and impaired target-cell co-stimulation. …
by, ru, us (code pays fourni par la source)
0 citations
medRxiv